Moving forward
MVT has developed a new, patented formulation, MVT-100, for use as an ultrasound contrast agent.
MVT-100 has a neutral surface chemistry, potentially serving as a platform for development of agents for molecular imaging and image-guided therapy. We've received formal guidance from the FDA that MVT-100 can be developed via the 505(b)(2) pathway.
The Company has designed an accelerated development pathway to potentially lead to approval of MVT-100 for echocardiography.
Momentum with MVT–100
PHASE 1 & 2
MVT–100
Indication:
Echocardiography
505b Pathway — Accelerated approval. Patent granted for improved microbubble formulation.
PRE-CLINICAL
MVT–101
Indication:
Sonothrombolysis - DVT, PE, ALI
MVT has right of reference to data showing efficacy of microbubble enhance sonothrombolysis using perflutren. MVT has exclusive right to condensed Phase Shift Microbubbles (PSMB).
• ISSUED PATENT
MVT–201
Indication:
Sonothrombolysis - MI, STroke
Targeted Phase Shift Microbubbles (PSMB)
• ISSUED PATENT
MVT–301
Indication:
Alzheimer's Disease
Dissolution of amyloid plaques in Alzheimer's using proprietary microbubbles and ultrasound.
• PROVISIONAL
MVT–401
Indication:
Pancreatic Cancer
Detection of pancreatic cancers <1MM in size.
• ISSUED PATENT
• IN-LICENCE
MVT–501
Indication:
Breast Cancer
Improved detection and differentiation on routine breast ultrasound, enabling faster, more accurate, and cheaper detection and treatment of breast cancer.
• ISSUED PATENT
MVT–601
Indication:
Uveitis
E-selection targeted microbubble for the diagnosis of uveitis. Potential for drug delivery and treatment of macular degeneration.
• ISSUED PATENT
• PATENT PENDING
